Nyxoah Initiates Leadership Transition, Searching for U.S.-Based CEO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Nyxoah announced the commencement of a leadership transition process. Following seven years leading Nyxoah, Olivier Taelman, together with the board of directors, has decided that this is the right moment to transition leadership to a U.S.-based CEO. The board has formally launched a search process to appoint a new U.S.-based CEO. Taelman will remain fully engaged during the transition period, continuing to lead the company's daily operations and to support an onboarding and transition to the future CEO.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NYXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NYXH
Wall Street analysts forecast NYXH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.880
Low
5.82
Averages
10.41
High
13.00
Current: 2.880
Low
5.82
Averages
10.41
High
13.00
About NYXH
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nyxoah Plans $95 Million Public Offering to Expand U.S. Operations
- Offering Details: Nyxoah is offering over 55 million ordinary shares to investors in the U.S. and Europe to raise $95 million, with a share price of $1.72 or €1.48, representing over a 40% discount to the last closing price, indicating strong market reactions to its valuation.
- Underwriter Option: Underwriters have the option to purchase an additional 8.3 million ordinary shares at the offering price within 30 days, providing the company with flexibility for further financing and potentially boosting market confidence.
- U.S. Expansion Plans: The funds raised will primarily be used to expand commercialization efforts in the U.S., and the company is seeking a U.S.-based CEO to enhance sales of its flagship product, Genio, demonstrating its commitment to the U.S. market.
- Retail Investor Sentiment Shift: On Stocktwits, retail sentiment regarding NYXH shifted from 'bearish' to 'extremely bullish' in the past 24 hours, reflecting optimistic expectations for the company's future despite its stock price having fallen over 80% in the last year.
See More
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
- Offering Size and Pricing: Nyxoah's public offering in the U.S. is priced at $1.72 per share, with expected gross proceeds of approximately $95 million, reflecting strong market interest in its OSA treatment technology and reinforcing its position in the medical technology sector.
- Planned Use of Funds: The proceeds will be allocated to expanding commercialization efforts in the U.S., further financing upgrades to the Genio system, and supporting clinical research for OSA patients, aiming to enhance product competitiveness and drive long-term growth for the company.
- Underwriters and Market Response: With BofA Securities acting as the lead underwriter, the offering is expected to close on June 9, 2026, indicating strong market confidence in Nyxoah and enhancing the company's activity in capital markets.
- Strategic Development and Collaboration Opportunities: Nyxoah plans to leverage the proceeds to explore potential collaborations in the field of OSA monitoring and diagnostics, demonstrating the company's strategic commitment to innovation and market expansion.
See More
Nyxoah Launches Proposed Public Offering in the U.S.
- Public Offering Announcement: Nyxoah has launched a proposed underwritten public offering of ordinary shares in the U.S., with all shares sold by the company and underwriters expected to receive a 30-day option to purchase an additional 15%, indicating confidence in market demand.
- Clear Use of Proceeds: The net proceeds from the offering are intended to support the commercialization of the Genio obstructive sleep apnea treatment system in the U.S. and other markets, fund R&D activities, and cover general corporate purposes, including working capital and potential debt repayment, reflecting the company's strategic growth planning.
- Market Condition Dependencies: The transaction remains subject to market and other conditions, showcasing the company's cautious approach in the current economic environment, which may affect investor confidence and market reactions.
- Undisclosed Size and Pricing: Although the company has not disclosed the size or pricing of the offering, this initiative could impact its stock performance, prompting investors to monitor subsequent information to assess investment risks and opportunities.
See More
Nyxoah Discloses Voting Rights and Share Information
- Share Issuance Details: On May 20, 2026, Nyxoah issued 1,031,323 new shares as part of a capital contribution linked to receivables from the holder of convertible bonds issued on December 18, 2025, thereby enhancing the company's capital structure.
- Equity and Voting Rights: The company's current share capital stands at EUR 6,521,361.42, with a total of 44,693,726 voting rights associated with all ordinary shares, ensuring shareholder participation and influence in corporate decisions.
- Convertible Bond Overview: Nyxoah has issued 225 convertible bonds with a nominal value of EUR 83,000 each, which could yield 3,735,000 voting rights upon full conversion, thereby strengthening shareholder equity.
- Potential Voting Rights Increase: If all convertible bonds are converted at the current price of EUR 5.00, 3,735,000 voting rights will be generated, while at a conversion price of EUR 2.18, the potential voting rights could rise to 8,566,513, indicating the company's flexibility and potential for future financing.
See More
Nyxoah Secures FDA Approval and Successful U.S. Launch
- FDA Approval and Market Launch: Nyxoah received FDA approval for Genio in August 2025 and successfully launched the product in the U.S. market, marking a significant advancement in the medical device sector that is expected to drive future revenue growth.
- Revenue and Training Success: By Q4 2025, Nyxoah generated $4.5 million in revenue after training 145 surgeons across 125 high-volume stimulation accounts, demonstrating its market penetration capabilities and enhancing its position in a competitive landscape.
- Global Revenue and Operating Loss: The company reported a global gross revenue of EUR 11 million for 2025, while total operating losses increased to EUR 83.5 million due to U.S. commercialization costs, reflecting the financial pressures faced during market expansion.
- Cash Flow and Market Penetration: With a quarterly cash burn rate of approximately EUR 20 million and a cash position of EUR 48 million, Nyxoah faces uncertainties regarding VAC approvals that could impact market penetration speed, necessitating close monitoring of future developments.
See More
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript
See More
Nyxoah Plans $95 Million Public Offering to Expand U.S. Operations
- Offering Details: Nyxoah is offering over 55 million ordinary shares to investors in the U.S. and Europe to raise $95 million, with a share price of $1.72 or €1.48, representing over a 40% discount to the last closing price, indicating strong market reactions to its valuation.
- Underwriter Option: Underwriters have the option to purchase an additional 8.3 million ordinary shares at the offering price within 30 days, providing the company with flexibility for further financing and potentially boosting market confidence.
- U.S. Expansion Plans: The funds raised will primarily be used to expand commercialization efforts in the U.S., and the company is seeking a U.S.-based CEO to enhance sales of its flagship product, Genio, demonstrating its commitment to the U.S. market.
- Retail Investor Sentiment Shift: On Stocktwits, retail sentiment regarding NYXH shifted from 'bearish' to 'extremely bullish' in the past 24 hours, reflecting optimistic expectations for the company's future despite its stock price having fallen over 80% in the last year.
See More
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
- Offering Size and Pricing: Nyxoah's public offering in the U.S. is priced at $1.72 per share, with expected gross proceeds of approximately $95 million, reflecting strong market interest in its OSA treatment technology and reinforcing its position in the medical technology sector.
- Planned Use of Funds: The proceeds will be allocated to expanding commercialization efforts in the U.S., further financing upgrades to the Genio system, and supporting clinical research for OSA patients, aiming to enhance product competitiveness and drive long-term growth for the company.
- Underwriters and Market Response: With BofA Securities acting as the lead underwriter, the offering is expected to close on June 9, 2026, indicating strong market confidence in Nyxoah and enhancing the company's activity in capital markets.
- Strategic Development and Collaboration Opportunities: Nyxoah plans to leverage the proceeds to explore potential collaborations in the field of OSA monitoring and diagnostics, demonstrating the company's strategic commitment to innovation and market expansion.
See More
Nyxoah Launches Proposed Public Offering in the U.S.
- Public Offering Announcement: Nyxoah has launched a proposed underwritten public offering of ordinary shares in the U.S., with all shares sold by the company and underwriters expected to receive a 30-day option to purchase an additional 15%, indicating confidence in market demand.
- Clear Use of Proceeds: The net proceeds from the offering are intended to support the commercialization of the Genio obstructive sleep apnea treatment system in the U.S. and other markets, fund R&D activities, and cover general corporate purposes, including working capital and potential debt repayment, reflecting the company's strategic growth planning.
- Market Condition Dependencies: The transaction remains subject to market and other conditions, showcasing the company's cautious approach in the current economic environment, which may affect investor confidence and market reactions.
- Undisclosed Size and Pricing: Although the company has not disclosed the size or pricing of the offering, this initiative could impact its stock performance, prompting investors to monitor subsequent information to assess investment risks and opportunities.
See More
Nyxoah Discloses Voting Rights and Share Information
- Share Issuance Details: On May 20, 2026, Nyxoah issued 1,031,323 new shares as part of a capital contribution linked to receivables from the holder of convertible bonds issued on December 18, 2025, thereby enhancing the company's capital structure.
- Equity and Voting Rights: The company's current share capital stands at EUR 6,521,361.42, with a total of 44,693,726 voting rights associated with all ordinary shares, ensuring shareholder participation and influence in corporate decisions.
- Convertible Bond Overview: Nyxoah has issued 225 convertible bonds with a nominal value of EUR 83,000 each, which could yield 3,735,000 voting rights upon full conversion, thereby strengthening shareholder equity.
- Potential Voting Rights Increase: If all convertible bonds are converted at the current price of EUR 5.00, 3,735,000 voting rights will be generated, while at a conversion price of EUR 2.18, the potential voting rights could rise to 8,566,513, indicating the company's flexibility and potential for future financing.
See More
Nyxoah Secures FDA Approval and Successful U.S. Launch
- FDA Approval and Market Launch: Nyxoah received FDA approval for Genio in August 2025 and successfully launched the product in the U.S. market, marking a significant advancement in the medical device sector that is expected to drive future revenue growth.
- Revenue and Training Success: By Q4 2025, Nyxoah generated $4.5 million in revenue after training 145 surgeons across 125 high-volume stimulation accounts, demonstrating its market penetration capabilities and enhancing its position in a competitive landscape.
- Global Revenue and Operating Loss: The company reported a global gross revenue of EUR 11 million for 2025, while total operating losses increased to EUR 83.5 million due to U.S. commercialization costs, reflecting the financial pressures faced during market expansion.
- Cash Flow and Market Penetration: With a quarterly cash burn rate of approximately EUR 20 million and a cash position of EUR 48 million, Nyxoah faces uncertainties regarding VAC approvals that could impact market penetration speed, necessitating close monitoring of future developments.
See More
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript
See More
